{
    "clinical_study": {
        "@rank": "35079", 
        "arm_group": {
            "arm_group_label": "Double staining with brilliant blue G during vitrectomy", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "Study designed to evaluate the safety and efficacy of double staining with brilliant blue G\n      0.025% as an adjuvant to macular surgery. Patients undergoing surgery for macular hole or\n      epiretinal membrane will be included. Safety will be evaluated by optic coherence\n      tomography, pattern reversal electroretinogram and multifocal electroretinogram."
        }, 
        "brief_title": "Safety and Efficacy of Double Staining With Brilliant Blue G for Macular Surgery", 
        "condition": [
            "Macular Hole", 
            "Epiretinal Membrane"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Retinal Perforations", 
                "Epiretinal Membrane"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patient age 18 years of older\n\n          -  Signing of informed consent\n\n          -  Macular pathology requiring vitrectomy (epiretinal membrane, macular hole,\n             vitreomacular traction syndrome)\n\n        Exclusion Criteria:\n\n          -  Diagnosis of glaucoma\n\n          -  Known allergy to brilliant blue G"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "90 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 26, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01820520", 
            "org_study_id": "RE11-09"
        }, 
        "intervention": {
            "arm_group_label": "Double staining with brilliant blue G during vitrectomy", 
            "description": "Double staining with brilliant blue G 0.025% for macular surgery", 
            "intervention_name": "brilliant blue G", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "March 27, 2013", 
        "location": {
            "contact": {
                "email": "retinamex@yahoo.com", 
                "last_name": "Antonieta Burgoa", 
                "phone": "+52(55)10841400", 
                "phone_ext": "1172"
            }, 
            "facility": {
                "address": {
                    "city": "Mexico City", 
                    "country": "Mexico", 
                    "state": "DF", 
                    "zip": "04030"
                }, 
                "name": "Asociaci\u00f3n para Evitar la Ceguera en M\u00e9xico"
            }, 
            "investigator": {
                "last_name": "Hugo Sep\u00falveda-V\u00e1zquez, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Mexico"
        }, 
        "number_of_arms": "1", 
        "official_title": "Safety and Efficacy of Double Staining With Brilliant Blue G for Macular Surgery", 
        "overall_contact": {
            "email": "hugo_dr14@hotmail.com", 
            "last_name": "Hugo Sep\u00falveda-V\u00e1zquez, MD", 
            "phone": "+52(55)10841400", 
            "phone_ext": "1172"
        }, 
        "overall_contact_backup": {
            "email": "jerry_gar@hotmail.com", 
            "last_name": "Gerardo Garcia-Aguirre, MD", 
            "phone": "+52(55)10841400", 
            "phone_ext": "1172"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Mexico: Secretaria de Salud", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "September 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Average thickness of ganglion cell layer - inner plexiform layer measured by spectral domain optical coherence tomography", 
                "measure": "Thickness of ganglion cell layer - inner plexiform layer measured by optical coherence tomography", 
                "safety_issue": "Yes", 
                "time_frame": "6 months"
            }, 
            {
                "description": "Amplitude of pattern reversal electroretinogram (in microvolts)", 
                "measure": "Amplitude of pattern reversal electroretinogram", 
                "safety_issue": "Yes", 
                "time_frame": "6 months"
            }, 
            {
                "description": "Measurement of the amplitude of the b-wave of multifocal electroretinogram", 
                "measure": "Amplitude of b-wave of multifocal electroretinogram", 
                "safety_issue": "Yes", 
                "time_frame": "6 months"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01820520"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Asociaci\u00f3n para Evitar la Ceguera en M\u00e9xico", 
            "investigator_full_name": "Hugo Sep\u00falveda-V\u00e1zquez", 
            "investigator_title": "Retina Fellow", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Visual acuity measured with an Early Treatment Diabetic Retinopathy Study chart", 
                "measure": "Visual acuity", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "description": "Presence of any ocular complication", 
                "measure": "Complications", 
                "safety_issue": "Yes", 
                "time_frame": "6 months"
            }
        ], 
        "source": "Asociaci\u00f3n para Evitar la Ceguera en M\u00e9xico", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Asociaci\u00f3n para Evitar la Ceguera en M\u00e9xico", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2013"
    }
}